Abstract

Tumor suppressor p53 exhibits an enigmatic phenotype in cells exposed to electrophilic, cyclopentenone prostaglandins of the A and J series. Namely, cells harboring a wild-type p53 gene accumulate p53 protein that is conformationally and functionally impaired. This occurs via an unknown molecular mechanism. We report that electrophilic cyclopentenone prostaglandins covalently modify and inhibit thioredoxin reductase, a selenoprotein that governs p53 and other redox-sensitive transcription factors. This mechanism accounts fully for the unusual p53 phenotype in cells exposed to electrophilic prostaglandins. Based on this mechanism we derived, tested, and affirmed several predictions regarding the kinetics of p53 inactivation; the protective effects of selenium; the structure-activity relationships for inhibition of thioredoxin reductase and impairment of p53 by electrophilic lipids; the susceptibility of hypoxia-inducible factor to inactivation by electrophilic lipids; and the equivalence of chemical inactivation of p53 to deletion of a p53 allele. Chemical precepts dictate that other electrophilic agents should also inhibit thioredoxin reductase and impair its governance of redox-sensitive proteins. Our results provide a novel framework to understand how endogenous and exogenous electrophiles might participate in carcinogenesis; how selenoproteins and selenium might confer protection against cancer; how certain tumors might acquire their paradoxical p53 phenotype; and how chronic inflammation might heighten the risk for cancer.

Highlights

  • Cyclopentenone prostaglandins (PG),1 of the A and J series impair the conformation and function of tumor suppressor p53 by a novel, but unknown, mechanism of action [1, 2]

  • Our results provide a novel framework to understand how endogenous and exogenous electrophiles might participate in carcinogenesis; how selenoproteins and selenium might confer protection against cancer; how certain tumors might acquire their paradoxical p53 phenotype; and how chronic inflammation might heighten the risk for cancer

  • We report that: (i) a prototypical PGA analog forms a covalent adduct with Thioredoxin reductase (TrxR); (ii) analogous to the cyclopentenone PG, several representative, naturally occurring or synthetic aldehydes and ketones with electrophilic ␤-carbons (15-ketoPG, 4-hydroxy-2-nonenal, and ethacrynic acid) impair p53 conformation and function, indirectly, via inhibition of TrxR; (iii) other redox-sensitive transcription factors governed by TrxRTrx cycling, e.g. hypoxia-inducible factor (HIF), are susceptible to inactivation by lipid aldehydes and ketones with electrophilic ␤-carbons; (iv) supplementation of cell culture medium with inorganic Se spares p53 from inactivation by lipid electrophiles; (v) impairment of p53 by lipid electrophiles is comparable in severity to loss of one allele of the p53 gene

Read more

Summary

Introduction

Cyclopentenone prostaglandins (PG),1 of the A and J series impair the conformation and function of tumor suppressor p53 by a novel, but unknown, mechanism of action [1, 2]. We report that electrophilic cyclopentenone prostaglandins covalently modify and inhibit thioredoxin reductase, a selenoprotein that governs p53 and other redox-sensitive transcription factors.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call